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acute OM. Although, considered a minor condition, OM often
disrupts the daily routine, forcing parents to stay at home. This
study was designed to investigate the productivity loss and soci-
etal burden of OM in several European countries. METHODS:
An internet-survey was conducted in 7 EU-countries: France(F),
Great Britain(GB), Germany(D), Spain(E), Italy(I), The Nether-
lands(NL), Belgium(B). Questions regarding the most recent
childhood-illness-episode included: symptoms, medical diagnosis
if medical help was sought, time taken off work, leisure time loss
and diminished productivity at work. Data were analyzed for
OM-episodes. RESULTS: 14916 parents of children (<5-years)
reported a child-illness-episode in the previous year, completing
an e-mailed 17-question-survey. A total of 1479 OM-episodes
were reported (65%–75% occurring in the previous month).
The proportion of parents seeking medical help ranged from
47%(NL) to 88.7%(E). In E, 27.9% of parents went to the
Emergency Room, 10–15% (D,I,GB); 2–4% (NL,B,F). Hospitali-
sation was required for 3.6–7.7% for an average 1.4–6.8 days.
12.8% (F,B)–21.7% (NL) parents took a median of 10–16 hours
off work. A further 23.4% (NL) to 82.4% (UK) parents reported
being less productive at work. In addition, 47.5% (D) to 68.1%
(B) said they had to take time out of their leisure time to visit the
doctor or the pharmacist. Children had an average of 2.2–2.7
episodes in the previous year; 28–57% had had 3 episodes in
the previous year. Indirect costs amounted to a total of €115.36
(NL) to €300.41 (UK) per episode. CONCLUSIONS: Indirect
costs due to lost productivity, either due to time taken off work,
reduced productivity at work or leisure time loss represents a
signiﬁcant proportion of the costs associated with OM. An inter-
vention that would reduce the incidence, prevalence or duration
of OM would have a major impact on the societal burden.
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OBJECTIVES: Several studies have shown that reducing the
intraocular pressure (IOP) of patients with glaucoma to a target
level 18 mmHg prevents further visual ﬁeld deterioration. The
objective of this analysis was to compare the IOP-lowering
efﬁcacy and the cost-effectiveness of ﬁxed combinations of
brimonidine/timolol and dorzolamide/timolol in 10 European
countries. METHODS: Efﬁcacy and safety of the two ﬁxed com-
bination products were based on pooled data from two head-to-
head trials. Efﬁcacy was measured as the percentage of patients
reaching an IOP level 18 mmHg or 13 mmHg after 3 months
of treatment. Discontinuation rates due to adverse events were
also included in the model, and it was assumed that patients
discontinuing treatment had an extra ophthalmologist visit. All
drug costs were market prices inclusive of VAT, and ophthal-
mologist visit costs were priced using ofﬁcial tariffs. RESULTS:
Clinical efﬁcacy data showed that brimonidine/timolol was more
effective than dorzolamide/timolol in terms of lowering patients’
IOP. The percentage of patients reaching IOP 13 mmHg was
32.65% for brimonidine/timolol and 13.95% for dorzolamide/
timolol (p = 0.0359). 77.55% of brimonidine/timolol patients
reached a target IOP  18 mmHg, and 60.47% of dorzolamide/
timolol patients did (p = 0.0756). Three months’ health care
costs for patients treated with brimonidine/timolol were compa-
rable to those of dorzolamide/timolol treatment in the 10 studied
countries. Brimonidine/timolol was less costly and more effective
in Italy, Spain, and Norway, whereas it was more effective and
slightly more costly in Germany, the UK, Denmark, Sweden, the
The Netherlands, Portugal and France. In these countries, the
incremental cost per patient reaching a target IOP  18 mmHg
ranged from £0.32 (UK) to €26.66 (The Netherlands). For IOP
 13 mm Hg the range was £0.29 (UK) to €24.36 (The Nether-
lands). CONCLUSIONS: Brimonidine/timolol is effective in
terms of lowering IOP and is a cost-effective treatment strategy
for patients with glaucoma.
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OBJECTIVES: To determine current treatment strategies and
evaluate one year consumption of health care resources for
patients with uveitis in France. METHODS: Data abstracted
from charts of consecutive patients (N = 100) from 4 French
referral centers with 12 months follow-up after the ﬁrst visit
included basic demographic data, clinical parameters, and all
disease- or treatment-related resource consumption. Direct
health care costs were estimated using publicly available stan-
dard unit costs. Indirect costs were based on standard sick leave
for each type of inpatient admission or outpatient intervention
and a gender-speciﬁc cost of employment. RESULTS: Most
patients (82%) were below age 60 (retirement age). Patients
had posterior uveitis (36%), panuveitis (33%), chronic anterior
(24%) and intermediate uveitis (7%). Patients received drug
treatments (91%), triamcinolone or dexamethasone injections
(8%), and laser treatment (2%). Mean direct costs per patient
were €3403 ($5045). Inpatient stays accounted for the largest
proportion, with a mean cost of €2889 ($4283) per year. For
patients below 60 years with an admission or intervention, the
estimated average productivity loss was €1750 ($2594), leading
to a mean indirect cost of €830 ($1230) per patient. The esti-
mated total minimum annual costs per patient were €4230
($6271). CONCLUSIONS: Annual treatment costs in this
sample were driven by frequent, extended inpatient stays. This
may be due to the more severely diseased patients who are
treated in these specialized centers. In the current sample, most
patients were of working age, suggesting a substantial amount of
indirect costs arising from sick leave.
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OBJECTIVES: Models have previously focused on short-term
costs and effectiveness measured in terms of intraocular (IOP)
control. This model will assess the long-term effects of continued
medical treatment in terms of glaucoma progression, low vision
and quality-of-life. METHODS: A cost-utility analysis using a
ten-year Markov model of ﬁrst-line latanoprost, bimatoprost,
travoprost or timolol, followed by second / third-line. Transition
probabilities for this model were from a systematic review and
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